Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: A randomized and open-label study

International Journal of COPD

Volumn 8, Issue , 2013, Pages 159-167

  Mehta, Rashmi ^a   Kelleher, Dennis ^a   Preece, Andrew ^b   Hughes, Stephen ^b   Crater, Glenn ^c  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c GLAXOSMITHKLINE   (Canada)

Author keywords

Long acting 2 agonist; Long acting muscarinic antagonist; Umeclidinium; Verapamil; Vilanterol

Indexed keywords

UMECLIDINIUM; VERAPAMIL; VILANTEROL;

ADULT; ADVERSE OUTCOME; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPEPSIA; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; LAST TIME POINT PLASMA CONCENTRATION; LIMIT OF QUANTITATION; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NIGHTMARE; NORMAL HUMAN; OPEN STUDY; OUTCOME ASSESSMENT; PARANOIA; PHARMACOLOGICAL PARAMETERS; POTASSIUM BLOOD LEVEL; PULSE RATE; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SLEEP DISORDER; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN; VOMITING;

LONG-ACTING Β2 AGONIST; LONG-ACTING MUSCARINIC ANTAGONIST; UMECLIDINIUM; VERAPAMIL; VILANTEROL;

ADMINISTRATION, ORAL; ADOLESCENT; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; BENZYL ALCOHOLS; CHLOROBENZENES; DRUG COMBINATIONS; DRY POWDER INHALERS; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; POTASSIUM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; VASODILATOR AGENTS; VERAPAMIL; YOUNG ADULT;

EID: 84875684910     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S40859     Document Type: Article

References (24)

1. Fletcher MJ, Upton J, Taylor-Fishwick J, etal. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011;11:612.
2. Mannino DM, Braman S. The epidemiology and economics of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2007;4(7): 502-506.
3. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523-532.
4. Ng TP, Niti M, Fones C, Yap KB, Tan WC. Co-morbid association of depression and COPD: a population-based study. Respir Med. 2009;103(6):895-901.
5. Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD. 2006;3(4):211-218.
6. GOLD: Global initiative for chronic obstructive lung disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2011). Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Feb21.pdf. Accessed November 23, 2012.
7. Gruffydd-Jones K, Loveridge C. The 2010NICE COPD Guidelines: how do they compare with the GOLD guidelines? Prim Care Respir J. 2011;20(2):199-204.
8. Fromer L, Cooper CB. A review of the GOLD guidelines for the diagnosis and treatment of patients with COPD. Int J Clin Pract. 2008;62(8): 1219-1236.
9. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149.
10. Cazzola M, Calzetta L, Matera MG. ß(2)-adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011;163(1):4-17.
11. Mehta R, Hardes K, Cahn A, etal. Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 Inhalation Powder, a new long-acting muscarinic antagonist, in healthy adults [abstract]. Eur Respir J. 2011a;38(Suppl 5):723s.
12. Cahn A, Lovick R, Newlands A, etal. Safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of GSK573719 inhalation powder in healthy subjects [abstract]. Eur Resp J. 2011;38(Suppl 55): 723s.
13. Mehta R, Newlands A, Kelleher D, Preece A, Cahn A, Crater G. Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of single doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist (LAMA), in patients with COPD. Eur Respir J. 2011;38(Suppl 55):138s.
14. Donohue J, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind, dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012;106(7):970-979.
15. Decramer M, Maltais F, Feldman G, etal. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol. 2013;185(2):393-399.
16. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26(2):256-264.
17. Procopiou PA, Barrett VJ, Bevan NJ, etal. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53(11):4522-4530.
18. Feldman G, Walker RR, Brooks J, Mehta R, Crater G. 28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25(6):465-471.
19. Kelleher DL, Mehta RS, Jean-Francois BM, etal. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS ONE. 2012;7(12):e50716.
20. US Food and Drug Administration. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. Draft Guidance. Silver Spring: US Food and Drug Administration; 2012. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed November 23, 2012.
21. World Medical Association. World Medical Association Declaration of Helsinki-Ethical Principles for Medical Research Involving Human Subjects. Seoul: 59th WMA General Assembly; 2008. Available from: http://www.wma.net/en/30publications/10policies/b3/17c.pdf. Accessed November 23, 2012.
22. GD Searle LLC. Calan (verapamil hydrochloride) [Package insert]. New York: GD Searle LLC, Division of Pfizer Inc; 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018817s024lbl.pdf. Accessed November 23, 2012.
23. Salpeter SR. Cardiovascular safety of beta(2)-andrenoceptor agonist use in patients with obstructive airway disease: a systematic review. Drugs Aging. 2004;21(6):405-414.
24. Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf. 2004;27(10):689-715.